Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Pharmacol Ther. Nov 6, 2013; 4(4): 120-126
Published online Nov 6, 2013. doi: 10.4292/wjgpt.v4.i4.120
Published online Nov 6, 2013. doi: 10.4292/wjgpt.v4.i4.120
Four-year follow-up of endoscopic gastroplication for the treatment of gastroesophageal reflux disease
Matthijs P Schwartz, Department of Gastroenterology, Meander Medical Center, 3800 BM Amersfoort, The Netherlands
J Rieneke C Schreinemakers, André J P M Smout, Department of Gastroenterology, University Medical Center, 3508 GA Utrecht, The Netherlands
Author contributions: Schwartz MP, Smout AJPM designed research; Schwartz MP performed research; Schwartz MP, Schreinemakers JRC analyzed data and wrote the paper; Schwartz MP, Smout AJPM revised the paper for final approval.
Correspondence to: Matthijs P Schwartz, MD, PhD, Department of Gastroenterology, Meander Medical Center, PO Box 1502, 3800 BM Amersfoort, The Netherlands. mp.schwartz@meandermc.nl
Telephone: +31-33-8501162 Fax: +31-33-8502631
Received: August 13, 2013
Revised: October 9, 2013
Accepted: October 15, 2013
Published online: November 6, 2013
Revised: October 9, 2013
Accepted: October 15, 2013
Published online: November 6, 2013
Core Tip
Core tip: The long-term efficacy of the first commercially available endoluminal suturing device for the treatment of gastroesophageal reflux disease (GERD), Endocinch, was evaluated. In the 4-year follow-up period, the subset of GERD patients that benefit from endoscopic gastroplication kept declining gradually. Up to 80% of patients again required acid-suppressive medication, making this endoscopic treatment procedure unsuccessful for the majority of GERD patients.